CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Status:
NOT_YET_RECRUITING
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.